Embodiments of the present disclosure relate to methods and apparatuses for dressing and treating a wound with negative or reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments disclosed herein relate to negative pressure therapy devices, methods for controlling the operation of TNP systems, and methods of using TNP systems.
In some embodiments, an apparatus for applying negative pressure to a wound is disclosed. The apparatus can include a housing, a pressure source, a first circuit board assembly, and a second circuit board assembly. The pressure source can be at least partially enclosed by the housing and provide negative pressure via a fluid flow path to a wound dressing. The first circuit board assembly can be at least partially enclosed by the housing and include a first controller configured to control a wound therapy with the wound dressing by activation and deactivation of the pressure source. The second circuit board assembly can be at least partially enclosed by the housing and in communication with the first circuit board assembly. The second circuit board assembly can be separate from the first circuit board assembly and include a second controller. The second controller can: communicate therapy data via a communication network, the therapy data being indicative of a characteristic of the wound therapy, receive an executable command from an electronic device, and execute the executable command without providing the executable command to the first controller.
The apparatus of the preceding paragraph can include one or more of the following features: The second controller can receive the executable command from the electronic device via a serial bus electrically connecting the second circuit board assembly and the electronic device. The second controller can receive the executable command from the electronic device via wireless communication. The second controller can wirelessly communicate the therapy data via the communication network. The electronic device may not be supported by the housing. The second controller can receive and execute the executable command without the wound therapy being interrupted. The second controller can receive and execute the executable command to test an operation of the second controller. The second controller can receive and execute the executable command despite the first controller not being operational. The executable command can be a request for hardware or software version data, and execution of the executable command by the second controller can cause the second controller to transmit the hardware or software version data to the electronic device. Execution of the executable command by the second controller can cause the second controller to change a setting associated with operation of the second controller. Execution of the executable command by the second controller can cause the second controller to communicate the therapy data via another communication network rather than the communication network. Execution of the executable command by the second controller can cause the second controller to perform an operation associated with the communication network. The executable command can be an attention (AT) command. The executable command can be a command of a Hayes command set. The second circuit board assembly can include a modem that includes the second controller. The apparatus can further include a third circuit board assembly including a connector interface, and the first hardware controller can receive another executable command via the connector interface from the electronic device. The second hardware controller can receive another executable command from the first hardware controller. The second hardware controller can enter (i) a data mode in which the data processed by the second hardware controller is not executed and (ii) a command mode in which data processed by the second hardware controller is executed. The first controller can gather the therapy data and provide the therapy data to the second controller for transmission. The second controller can receive another executable command from the electronic device and provide the another executable command to the first controller for execution.
In some embodiments, a method is disclosed for operating a wound therapy device that includes a first circuit board assembly and a second circuit board assembly separate from the first circuit board assembly. The method can include, by a first controller mounted to the first circuit board assembly, controlling application of negative pressure with a pressure source to a wound dressing. In addition, the method can include by a second controller mounted to the second circuit board assembly: communicating therapy data via a communication network, the therapy data being indicative of a characteristic of wound therapy performed with the pressure source, receiving an executable command from an electronic device, and executing the executable command without processing the executable command with the first controller.
The method of the preceding paragraph can include one or more of the following features: The receiving can include receiving the executable command from the electronic device via a serial bus electrically connecting the second circuit board assembly and the electronic device. The receiving can include receiving the executable command from the electronic device via wireless communication. The communicating can include wirelessly communicating the therapy data via the communication network. The receiving and executing can include receiving and executing the executable command without the wound therapy being interrupted. The executing can include executing the executable command to test an operation of the second controller. The receiving and executing can include receiving and executing the executable command despite the first controller not being operational. The executable command can be a request for hardware or software version data, and the executing can cause the second controller to transmit the hardware or software version data to the electronic device. The executing can cause the second controller to change a setting associated with operation of the second controller. The executing can cause the second controller to communicate the therapy data via another communication network rather than the communication network.
Features and advantages of the present disclosure will be apparent from the following detailed description, taken in conjunction with the accompanying drawings of which:
The present disclosure relates to methods and apparatuses for dressing and treating a wound with reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments of this disclosure relate to negative pressure therapy apparatuses, methods for controlling the operation of TNP systems, and methods of using TNP systems. The methods and apparatuses can incorporate or implement any combination of the features described below.
Many different types of wound dressings are known for aiding in the healing process of a human or animal. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. TNP therapy, sometimes referred to as vacuum assisted closure, negative pressure wound therapy, or reduced pressure wound therapy, can be a beneficial mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.
TNP therapy can assist in the closure and healing of wounds by reducing tissue oedema, encouraging blood flow, stimulating the formation of granulation tissue, removing excess exudates, and reducing bacterial load and thus, infection to the wound. Furthermore, TNP therapy can permit less outside disturbance of the wound and promote more rapid healing.
As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below atmospheric pressure, which typically corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects pressure that is X mmHg below atmospheric pressure, such as a pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (for example, −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (for example, −80 mmHg is more than −60 mmHg).
A pump assembly of a TNP system can include multiple controllers or processors used to control the various operations of the pump assembly. A main controller can, for example, be used to orchestrate an overall functioning of the pump assembly, and one or more other controllers can be used to control one or more specialized functions of the pump assembly (such as communications, negative pressure control, or user interface operations) under direction from the main controller.
A pump assembly can communicate with an electronic device that is separate from the pump assembly by having a main controller of the pump assembly exchange messages with the electronic device. The electronic device may, for instance, transmit an executable command as part of a message to the main controller. The main controller can then receive and process the message and execute the executable command or pass along the executable command for execution by one or more other controllers of the pump assembly.
If a main controller of a pump assembly is the sole channel through which an electronic device can communicate particular information between the electronic device and one or more other controllers of the pump assembly, this can be undesirable in certain instances because the main controller can introduce delay, control limits, or errors to the communication between the electronic device and the one or more other controllers. In certain instances, the main controller may devote resources to communicating with the electronic device, which may negatively affect (for example, delay or interrupt) provision of negative pressure wound therapy.
The pump assemblies as described herein can overcome such challenges, in certain embodiments, by enabling communication between the electronic device and the one or more other controllers without relying on the main controller to serve as an intermediary for the communication. The lack of the intermediary moreover can be particularly advantageous, in certain embodiments, when device testing and troubleshooting at least because testing and troubleshooting can be made easier and faster through direct rather than indirect communication.
In some embodiments, a pump assembly can include a communications controller (for instance, a wireless/GPS controller) that may directly communicate with an electronic device without a main controller of the pump assembly functioning as an arbiter between the electronic device and the communications controller. The communications between the electronic device and the communications controller can be via wired communication (for instance, Universal Serial Bus (USB) communication) or wireless communication. The electronic device can send executable commands, such as attention (AT) commands, to the communications controller for execution by the communications controller. One executable command can, for example, cause the communications controller to transition from operating on one network to operating on a different network, such as from a cellular network operated by one provider to a different cellular network operated by a different provider. Moreover; the electronic device can communicate about or change settings of the communications controller without affecting (for example, interrupting) therapy being performed by the pump assembly under control of the main controller.
System Overview
The wound filler 130 can be any suitable type, such as hydrophilic or hydrophobic foam, gauze, inflatable bag, and so on. The wound filler 130 can be conformable to the wound cavity 110 such that it substantially fills the cavity. The wound cover 120 can provide a substantially fluid impermeable seal over the wound cavity 110. The wound cover 120 can have a top side and a bottom side, and the bottom side adhesively (or in any other suitable manner) seals with wound cavity 110. The conduit 140 or lumen or any other conduit or lumen disclosed herein can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any other suitable material.
Some embodiments of the wound cover 120 can have a port (not shown) configured to receive an end of the conduit 140. For example, the port can be Renays Soft Port available from Smith & Nephew. In other embodiments, the conduit 140 can otherwise pass through or under the wound cover 120 to supply reduced pressure to the wound cavity 110 so as to maintain a desired level of reduced pressure in the wound cavity. The conduit 140 can be any suitable article configured to provide at least a substantially sealed fluid flow pathway between the pump assembly 150 and the wound cover 120, so as to supply the reduced pressure provided by the pump assembly 150 to wound cavity 110.
The wound cover 120 and the wound filler 130 can be provided as a single article or an integrated single unit. In some embodiments, no wound filler is provided and the wound cover by itself may be considered the wound dressing. The wound dressing may then be connected, via the conduit 140, to a source of negative pressure, such as the pump assembly 150. The pump assembly 150 can be miniaturized and portable, although larger conventional pumps such can also be used.
The wound cover 120 can be located over a wound site to be treated. The wound cover 120 can form a substantially sealed cavity or enclosure over the wound site. In some embodiments, the wound cover 120 can be configured to have a film having a high water vapor permeability to enable the evaporation of surplus fluid, and can have a superabsorbing material contained therein to safely absorb wound exudate. It will be appreciated that throughout this specification reference is made to a wound. In this sense it is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other surficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, acute wounds, chronic wounds, surgical incisions and other incisions, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. The components of the TNP system described herein can be particularly suited for incisional wounds that exude a small amount of wound exudate.
Some embodiments of the system are designed to operate without the use of an exudate canister. Some embodiments can be configured to support an exudate canister. In some embodiments, configuring the pump assembly 150 and tubing 140 so that the tubing 140 can be quickly and easily removed from the pump assembly 150 can facilitate or improve the process of dressing or pump changes, if necessary. Any of the pump embodiments disclosed herein can be configured to have any suitable connection between the tubing and the pump.
The pump assembly 150 can be configured to deliver negative pressure of approximately −80 mmHg, or between about −20 mmHg and 200 mmHg in some implementations. Note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms. The pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also a pressure range of below −75 mmHg can be used. Alternatively a pressure range of over approximately −100 mmHg, or even 150 mmHg, can be supplied by the pump assembly 150.
In operation, the wound filler 130 is inserted into the wound cavity 110 and wound cover 120 is placed so as to seal the wound cavity 110. The pump assembly 150 provides a source of a negative pressure to the wound cover 120, which is transmitted to the wound cavity 110 via the wound filler 130. Fluid (e.g., wound exudate) is drawn through the conduit 140, and can be stored in a canister. In some embodiments, fluid is absorbed by the wound filler 130 or one or more absorbent layers (not shown).
Wound dressings that may be utilized with the pump assembly and other embodiments of the present application include Renasys-F, Renasys-G, Renasys AB, and Pico Dressings available from Smith & Nephew. Further description of such wound dressings and other components of a negative pressure wound therapy system that may be used with the pump assembly and other embodiments of the present application are found in U.S. Patent Publication Nos. 2011/0213287, 2011/0282309, 2012/0116334, 2012/0136325, and 2013/0110058, which are incorporated by reference in their entirety. In other embodiments, other suitable wound dressings can be utilized.
The pump assembly 230 includes one or more indicators, such as visual indicator 202 configured to indicate alarms and visual indicator 204 configured to indicate status of the TNP system. The indicators 202 and 204 can be configured to alert a user, such as patient or medical care provider, to a variety of operating or failure conditions of the system, including alerting the user to normal or proper operating conditions, pump failure, power supplied to the pump or power failure, detection of a leak within the wound cover or flow pathway, suction blockage, or any other similar or suitable conditions or combinations thereof. The pump assembly 230 can comprise additional indicators. The pump assembly can use a single indicator or multiple indicators. Any suitable indicator can be used such as visual, audio, tactile indicator, and so on. The indicator 202 can be configured to signal alarm conditions, such as canister full, power low, conduit 140 disconnected, seal broken in the wound seal 120, and so on. The indicator 202 can be configured to display red flashing light to draw user's attention. The indicator 204 can be configured to signal status of the TNP system, such as therapy delivery is ok, leak detected, and so on. The indicator 204 can be configured to display one or more different colors of light, such as green, yellow, etc. For example, green light can be emitted when the TNP system is operating properly and yellow light can be emitted to indicate a warning.
The pump assembly 230 includes a display or screen 206 mounted in a recess 208 formed in a case of the pump assembly. The display 206 can be a touch screen display. The display 206 can support playback of audiovisual (AV) content, such as instructional videos. As explained below, the display 206 can be configured to render a number of screens or graphical user interfaces (GUIs) for configuring, controlling, and monitoring the operation of the TNP system. The pump assembly 230 comprises a gripping portion 210 formed in the case of the pump assembly. The gripping portion 210 can be configured to assist the user to hold the pump assembly 230, such as during removal of the canister 220. The canister 220 can be replaced with another canister, such as when the canister 220 has been filled with fluid.
The pump assembly 230 includes one or more keys or buttons 212 configured to allow the user to operate and monitor the operation of the TNP system. As is illustrated, there buttons 212a, 212b, and 212c are included. Button 212a can be configured as a power button to turn on/off the pump assembly 230. Button 212b can be configured as a play/pause button for the delivery of negative pressure therapy. For example, pressing the button 212b can cause therapy to start, and pressing the button 212b afterward can cause therapy to pause or end. Button 212c can be configured to lock the display 206 or the buttons 212. For instance, button 212c can be pressed so that the user does not unintentionally alter the delivery of the therapy. Button 212c can be depressed to unlock the controls. In other embodiments, additional buttons can be used or one or more of the illustrated buttons 212a, 212b, or 212c can be omitted. Multiple key presses or sequences of key presses can be used to operate the pump assembly 230.
The pump assembly 230 includes one or more latch recesses 222 formed in the cover. In the illustrated embodiment, two latch recesses 222 can be formed on the sides of the pump assembly 230. The latch recesses 222 can be configured to allow attachment and detachment of the canister 220 using one or more canister latches 221. The pump assembly 230 comprises an air outlet 224 for allowing air removed from the wound cavity 110 to escape. Air entering the pump assembly can be passed through one or more suitable filters, such as antibacterial filters. This can maintain reusability of the pump assembly. The pump assembly 230 includes one or more strap mounts 226 for connecting a carry strap to the pump assembly 230 or for attaching a cradle. In the illustrated embodiment, two strap mounts 226 can be formed on the sides of the pump assembly 230. In some embodiments, various of these features are omitted or various additional features are added to the pump assembly 230.
The canister 220 is configured to hold fluid (e.g., exudate) removed from the wound cavity 110. The canister 220 includes one or more latches 221 for attaching the canister to the pump assembly 230. In the illustrated embodiment, the canister 220 comprises two latches 221 on the sides of the canister. The exterior of the canister 220 can formed from frosted plastic so that the canister is substantially opaque and the contents of the canister and substantially hidden from plain view. The canister 220 comprises a gripping portion 214 formed in a case of the canister. The gripping portion 214 can be configured to allow the user to hold the pump assembly 220, such as during removal of the canister from the apparatus 230. The canister 220 includes a substantially transparent window 216, which can also include graduations of volume. For example, the illustrated 300 mL canister 220 includes graduations of 50 mL, 100 mL, 150 mL, 200 mL, 250 mL, and 300 mL. Other embodiments of the canister can hold different volume of fluid and can include different graduation scale. For example, the canister can be an 800 canister. The canister 220 comprises a tubing channel 218 for connecting to the conduit 140. In some embodiments, various of these features, such as the gripping portion 214, are omitted or various additional features are added to the canister 220. Any of the disclosed canisters may include or may omit a solidifier.
The canister 220 includes one or more feet 244 for placing the canister on a surface. The feet 244 can be formed out of rubber, silicone, or any other suitable material and can be angled at a suitable angle so that the canister 220 remains stable when placed on the surface. The canister 220 comprises a tube mount relief 246 configured to allow one or more tubes to exit to the front of the device. The canister 220 includes a stand or kickstand 248 for supporting the canister when it is placed on a surface. As explained below, the kickstand 248 can pivot between an opened and closed position. In closed position, the kickstand 248 can be latched to the canister 220. The kickstand 248 can be made out of an opaque material, such as plastic, or a transparent material. The kickstand 248 includes a gripping portion 242 formed in the kickstand. The gripping portion 242 can be configured to allow the user to place the kickstand 248 in the closed position. The kickstand 248 comprises a hole 249 to allow the user to place the kickstand in the open position. The hole 249 can be sized to allow the user to extend the kickstand using a finger.
A pump assembly may include one or more additional or alternative access mechanisms, such as illustrated with respect to
The pump assembly can comprise a user interface processor or controller 310 that can function as a main processor and be configured to operate one or more components for accepting user input and providing output to the user, such as the display 206, buttons 212, etc. Input to the pump assembly and output from the pump assembly can controlled by an input/output (I/O) module 320, For example, the I/O module can receive data from one or more ports, such as serial, parallel, hybrid ports, and the like. The processor 310 also receives data from and provides data to one or more expansion modules 360, such as one or more USB ports, SD ports, CD drives, DVD drives, FireWire ports, Thunderbolt ports, PCI Express ports, and the like. The processor 310, along with other controllers or processors, stores data in one or more memory modules 350, which can be internal or external to the processor 310. Any suitable type of memory can be used, including volatile or non-volatile memory, such as RAM, ROM, magnetic memory, solid-state memory, magnetoresistive random-access memory (MRAM), and the like.
In some embodiments, the processor 310 can be a general purpose controller, such as a low-power processor. In other embodiments, the processor 310 can be an application specific processor. The processor 310 can be configured as a “central” processor in the electronic architecture of the pump assembly, and the processor 310 can coordinate the activity of other processors, such as a pump control processor 370, communications processor 330, and one or more additional processors 380 (e.g., processor for controlling the display 206, processor for controlling the buttons 212, etc.). The processor 310 can run a suitable operating system, such as a Linux, Windows CE, V×Works, etc.
The pump control processor 370 can be configured to control the operation of a negative pressure pump 390. The pump 390 can be a suitable pump, such as a diaphragm pump, peristaltic pump, rotary pump, rotary vane pump, scroll pump, screw pump, liquid ring pump, diaphragm pump operated by a piezoelectric transducer, voice coil pump, and the like. The pump control processor 370 can measure pressure in a fluid flow path, using data received from one or more pressure sensors, calculate the rate of fluid flow, and control the pump. The pump control processor 370 can control a pump motor so that a desired level of negative pressure is achieved in the wound cavity 110. The desired level of negative pressure can be pressure set or selected by the user. In various embodiments, the pump control processor 370 controls the pump (e.g., pump motor) using pulse-width modulation (PWM). A control signal for driving the pump can be a 0-100% duty cycle PWM signal. The pump control processor 370 can perform flow rate calculations and detect various conditions in a flow path. The pump control processor 370 can communicate information to the processor 310. The pump control processor 370 can include internal memory or can utilize memory 350. The pump control processor 370 can be a low-power processor.
A communications processor 330 can be configured to provide wired or wireless connectivity. The communications processor 330 can utilize one or more antennas 340 for sending and receiving data. The communications processor 330 can provide one or more of the following types of connections: Global Positioning System (GPS) technology, cellular connectivity (e.g., 2G, 3G, LTE, 4G, 5G, SIM chip), WiFi connectivity, Internet connectivity, and the like. Connectivity can be used for various activities, such as pump assembly location tracking, asset tracking, compliance monitoring, remote selection, uploading of logs, alarms, and other operational data, and adjustment of therapy settings, upgrading of software or firmware, and the like. The communications processor 330 can provide dual GPS/cellular functionality. Cellular functionality can, for example, be 3G functionality. The pump assembly can include a subscriber identity module (SIM) card, and SIM-based positional information can be obtained.
The communications processor 330 can also be electrically coupled to one or more serial, parallel, or hybrid data transfer connector interfaces or another type of interface through which the communications processor 330 can directly receive data or commands without receiving the data or commands through or from the processor 310. For instance, the data transfer connector interfaces can include one or more USB ports, SD ports, CD drives, DVD drives, FireWire ports, Thunderbolt ports, PCI Express ports, and the like. The data transfer connector interfaces can, for instance, be part of the communications processor 330 or part of the input/output (I/O) module 320.
The communications processor 330 can communicate information to the processor 310 and receive information from the processor 310. The communications processor 330 can include internal memory or can utilize memory 350. The communications processor 330 can be a low-power processor.
Using the connectivity provided by the communications processor 330, the device can upload any of the data stored, maintained, or tracked by the pump assembly. The device can also download various operational data, such as therapy selection and parameters, firmware and software patches and upgrades, and the like.
The communications processor 330 can receive and execute an executable command from the electronic device 392 without interrupting wound therapy being performed by the pump assembly 300 and without the processor 310 being operational (for instance, powered). Moreover, the communications processor 330 can receive and execute an executable command from the electronic device 392 that instructs and causes the communications processor 330 to: test an operation of the communications processor 330, transmit the hardware or software version data for the communications processor 330 to the electronic device 392, change a setting associated with operation of the communications processor 330, communicate data via one communication network rather than another communication network, perform an operation associated with a communication network over which the communications processor 330 transmits data, or the like. The communications processor 330 can enter a data mode in which data processed by the communications processor 330 is not executed and a command mode in which data processed by the communications processor 330 is executed. In some implementations, the communication processor 330 can execute certain executable commands (such as those described herein) directly without communicating such commands to or otherwise involving the processor 310. The communication processor 330 can communicate to or otherwise involve the processor 310 for execution of certain other executable commands, such as executable commands that relate to provision of therapy.
In one implementation, the electronic device 392 can be a personal computer (PC) that communicates with the pump assembly 300. The electronic device 392 can be first connected to the pump assembly 300 and the pump assembly 300—or at least the communications processor 330—can be unpowered. The pump assembly 300—or at least the communications processor 330—can then be powered and a wait period of 30 seconds can be initiated and completed. On the electronic device 392, a terminal program (for instance, PuTTY HyperTerminal) can next be opened and connected to a communications port through which the electronic device 392 is connected to the pump assembly 300. The terminal program can subsequently be used to provide executable commands to the communications processor 330, and the terminal program can display any responses from the communications processor 330.
Although
Although
Device Electronics and Communication
The wireless communications controller 810 can communicate with the main microcontroller 820 via a first path 812A electrically connecting contacts HDA_P and HDA1_P and a second path 812B electrically connecting contacts HDA_N to HDA1_N. The wireless communications controller 810 can communicate with the connector port 830 via a third path 814A electrically connecting contacts HDA_P and HDA2_P and a fourth path 814B electrically connecting contacts HDA_N to HDA2_N. In operation, one of the first and second paths 812A, 812B or the third and fourth paths 814A, 814B may be connected at a time so that either the main microcontroller 820 or the connector port 830 may communicate with the wireless communications controller 810, For example, resistors R16, R17 can be activated or conducting and resistors R14, R15 may not be activated or conducting when the wireless communications controller 810 communicates with the connector port 830, and the resistors R14, R15 can be activated or conducting and the resistors R16, R17 may not be activated or conducting when the wireless communications controller 810 communicates with the main microcontroller 820. In some implementations, resistors R14, R15, R16, and R17 can be replaced with two or more dip switches, relays, or the like to permit connection of the wireless communications controller 810 to the main microcontroller 820 or the connector port 830.
The first and second switches 840A, 840B can, for instance, be part of one or more dual in-line package (DIP) switches. In certain embodiments, the implementation of the various components 800A can be preferred over the implementation of the various components 800B because the first and second switches 840A, 840B may introduce noise or other negative signal artifacts that impede communication with the wireless communications controller 810.
The first and second switches 840A, 840B can, in some implementations, be smart switches, such as analog relay switches, that may be commanded via software. In one example, a display of a pump assembly, such as the display 206, can present a user input that is selected to control a state of one or both of the first and second switches 840A, 840B. In another example, a state of one or both of the first and second switches 840A, 840B can be adjusted via remote communication between a pump assembly and another electronic device. The first and second switches 840A, 840B can be controlled as a serial communication router (for instance, USB, SPI, I2C, or the like), multiplexers, or analog switches. The first and second switches 840A, 840B can be one-time or multi-use fuses in some implementations, which can be desirable in some cases for preprograming code or settings in the wireless communications controller 810 and securing later.
The first and second switches 840A, 840B can be designed so that the pump assembly with the first and second switches 840A, 840B may pass wireless coexistence adjacent channel selectivity testing (for instance, 3G wireless coexistence adjacent channel selectivity testing). The first and second switches 840A, 840B can access the wireless communications controller 810 via another electronic device or a special tool and may be used to analyze or troubleshoot a break in device security. The another electronic device or special tool can moreover send an AT command that allows the another electronic device or special tool to test a carrier for the pump assembly (for example, a cellular network on which the pump assembly communicates using the wireless communications controller 810). In the event of a software or hardware failure or a safety failure, such as to the main microcontroller 820 or another controller of the pump assembly other than the wireless communications controller 810, the first and second switches 840A, 840B can help with analyzing the communication channel between the wireless communications controller 810 and the main microcontroller 820. In some implementations, a SIM card can be connected to the wireless communications controller 810.
Although
At block 1102, the process 1100 can control application of negative pressure. For example, the processor 310 can instruct and cause the pump control processor 370 to start or stop provision of negative pressure with the pump 390.
At block 1104, the process 1100 can communicate therapy data via a communication network. For example, the processor 310 can instruct and cause the communications processor 330 to wirelessly transmit therapy data indicative of a characteristic of wound therapy performed by the pump assembly 300 via the network 396 to the data processing system 394.
At block 1106, the process 1100 can receive an executable command. For example, the communications processor 330 can receive an executable command from the external device 392.
At block 1108, the process 1100 can execute the executable command. For example, the communications processor 330 can execute the executable command causing the communications processor 330 to perform one or more operations, such as to test an operation of the communications processor 330, transmit hardware or software version data for the communications processor 330, change a setting associated with operation of the communications processor 330, or transition from communicating therapy data one communication network to a different communication network. The communications processor 330 moreover may execute the command without the processor 310 processing the executable command or without providing the executable command to the processor 310.
Other Variations and Terminology
The communications processor 330 of
Any value of a threshold, limit, duration, etc. provided herein is not intended to be absolute and, thereby, can be approximate. In addition, any threshold, limit, duration, etc. provided herein can be fixed or varied either automatically or by a user. Furthermore, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass being equal to the reference value. For example, exceeding a reference value that is positive can encompass being equal to or greater than the reference value. In addition, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass an inverse of the disclosed relationship, such as below, less than, greater than, etc. in relations to the reference value. Moreover, although blocks of the various processes may be described in terms of determining whether a value meets or does not meet a particular threshold, the blocks can be similarly understood, for example, in terms of a value (i) being below or above a threshold or (ii) satisfying or not satisfying a threshold.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figure. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.
Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.
The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
This application is a U.S. national stage application of International Patent Application No. PCT/US2018/041313, filed Jul. 9, 2018, which claims the benefit of U.S. Provisional Application No. 62/530,480, filed Jul. 10, 2017; the disclosure of which is hereby incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/041313 | 7/9/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/014141 | 1/17/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
695270 | Beringer | Mar 1902 | A |
3194239 | Sullivan et al. | Jul 1965 | A |
4832299 | Gorton et al. | May 1989 | A |
5219428 | Stern | Jun 1993 | A |
5473536 | Wimmer | Dec 1995 | A |
5960403 | Brown | Sep 1999 | A |
6055506 | Frasca et al. | Apr 2000 | A |
6336900 | Alleckson et al. | Jan 2002 | B1 |
6353445 | Babula et al. | Mar 2002 | B1 |
6375614 | Braun et al. | Apr 2002 | B1 |
6385622 | Bouve et al. | May 2002 | B2 |
6406426 | Reuss et al. | Jun 2002 | B1 |
6434572 | Derzay et al. | Aug 2002 | B2 |
6460041 | Lloyd | Oct 2002 | B2 |
6574518 | Lounsberry et al. | Jun 2003 | B1 |
6640145 | Hoffberg et al. | Oct 2003 | B2 |
6640246 | Gary et al. | Oct 2003 | B1 |
6675131 | Hahn | Jan 2004 | B2 |
6681003 | Linder et al. | Jan 2004 | B2 |
6723046 | Lichtenstein et al. | Apr 2004 | B2 |
6730024 | Freyre et al. | May 2004 | B2 |
6747556 | Medema et al. | Jun 2004 | B2 |
6779024 | Delahuerga | Aug 2004 | B2 |
6782285 | Birkenbach et al. | Aug 2004 | B2 |
6856825 | Hahn | Feb 2005 | B2 |
6868528 | Roberts | Mar 2005 | B2 |
6871211 | Labounty et al. | Mar 2005 | B2 |
6909974 | Yung et al. | Jun 2005 | B2 |
6912481 | Breunissen et al. | Jun 2005 | B2 |
6961731 | Holbrook | Nov 2005 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7051012 | Cole et al. | May 2006 | B2 |
7062251 | Birkett et al. | Jun 2006 | B2 |
7066883 | Schmidt et al. | Jun 2006 | B2 |
7103578 | Beck et al. | Sep 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7120488 | Nova et al. | Oct 2006 | B2 |
7133869 | Bryan et al. | Nov 2006 | B2 |
7167858 | Naeymi-Rad et al. | Jan 2007 | B2 |
7212829 | Lau et al. | May 2007 | B1 |
7264591 | Brown | Sep 2007 | B2 |
7300418 | Zaleski | Nov 2007 | B2 |
7304573 | Postma | Dec 2007 | B2 |
7311665 | Hawthorne et al. | Dec 2007 | B2 |
7333002 | Bixler et al. | Feb 2008 | B2 |
7353179 | Ott et al. | Apr 2008 | B2 |
7384267 | Franks et al. | Jun 2008 | B1 |
7430598 | Raden et al. | Sep 2008 | B2 |
7430608 | Noonan et al. | Sep 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7451002 | Choubey | Nov 2008 | B2 |
7457804 | Uber et al. | Nov 2008 | B2 |
7460872 | Millard et al. | Dec 2008 | B2 |
7534240 | Johnson | May 2009 | B1 |
7598855 | Scalisi et al. | Oct 2009 | B2 |
7608066 | Vogel | Oct 2009 | B2 |
7627334 | Cohen et al. | Dec 2009 | B2 |
7649449 | Fenske et al. | Jan 2010 | B2 |
7671733 | McNeal et al. | Mar 2010 | B2 |
7684999 | Brown | Mar 2010 | B2 |
7698156 | Martucci et al. | Apr 2010 | B2 |
7734764 | Weiner et al. | Jun 2010 | B2 |
7749164 | Davis | Jul 2010 | B2 |
7758555 | Kelch et al. | Jul 2010 | B2 |
7779153 | Van Den Heuvel et al. | Aug 2010 | B2 |
7789828 | Clapp | Sep 2010 | B2 |
7794438 | Henley et al. | Sep 2010 | B2 |
7827148 | Mori et al. | Nov 2010 | B2 |
7865375 | Lancaster et al. | Jan 2011 | B2 |
7889069 | Fifolt et al. | Feb 2011 | B2 |
7890887 | Linardos et al. | Feb 2011 | B1 |
7912823 | Ferrari et al. | Mar 2011 | B2 |
7925603 | Laidig et al. | Apr 2011 | B1 |
7933817 | Radl et al. | Apr 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
7988850 | Roncadi et al. | Aug 2011 | B2 |
8015443 | Adachi | Sep 2011 | B2 |
8015972 | Pirzada | Sep 2011 | B2 |
8019618 | Brown | Sep 2011 | B2 |
8036925 | Choubey | Oct 2011 | B2 |
8054950 | Hung et al. | Nov 2011 | B1 |
8069057 | Choubey et al. | Nov 2011 | B2 |
8094009 | Allen et al. | Jan 2012 | B2 |
8126735 | Dicks et al. | Feb 2012 | B2 |
8130095 | Allen et al. | Mar 2012 | B2 |
8131472 | Chow et al. | Mar 2012 | B2 |
8180750 | Wilmering et al. | May 2012 | B2 |
8190445 | Kuth et al. | May 2012 | B2 |
8190448 | Bajars et al. | May 2012 | B2 |
8228188 | Key et al. | Jul 2012 | B2 |
8246606 | Stevenson et al. | Aug 2012 | B2 |
8249894 | Brown | Aug 2012 | B2 |
8255241 | Cafer | Aug 2012 | B2 |
8260630 | Brown | Sep 2012 | B2 |
8280682 | Vock et al. | Oct 2012 | B2 |
8284046 | Allen et al. | Oct 2012 | B2 |
8290792 | Sekura | Oct 2012 | B2 |
8291337 | Gannin et al. | Oct 2012 | B2 |
8323263 | Wood et al. | Dec 2012 | B2 |
8332233 | Ott et al. | Dec 2012 | B2 |
8332236 | Yurko et al. | Dec 2012 | B2 |
8334768 | Eaton et al. | Dec 2012 | B2 |
8337482 | Wood et al. | Dec 2012 | B2 |
8360975 | Schwieterman et al. | Jan 2013 | B1 |
8400295 | Khaira | Mar 2013 | B1 |
8422377 | Weiner et al. | Apr 2013 | B2 |
8424517 | Sutherland et al. | Apr 2013 | B2 |
8436871 | Alberte | May 2013 | B2 |
8439882 | Kelch | May 2013 | B2 |
8457740 | Osche | Jun 2013 | B2 |
8480641 | Jacobs | Jul 2013 | B2 |
8515776 | Schoenberg | Aug 2013 | B2 |
8532764 | Duke | Sep 2013 | B2 |
8540688 | Eckstein et al. | Sep 2013 | B2 |
8545483 | Schwabe et al. | Oct 2013 | B2 |
8554195 | Rao | Oct 2013 | B2 |
8554902 | Ebert et al. | Oct 2013 | B2 |
8558964 | Bedingfield | Oct 2013 | B2 |
8560082 | Wei | Oct 2013 | B2 |
8577694 | Kanaan | Nov 2013 | B2 |
8595553 | Goertler et al. | Nov 2013 | B2 |
8600777 | Schoenberg et al. | Dec 2013 | B2 |
8626342 | Williams et al. | Jan 2014 | B2 |
8626526 | Lemke et al. | Jan 2014 | B2 |
8630660 | Ray et al. | Jan 2014 | B2 |
8632485 | Schlaeper et al. | Jan 2014 | B2 |
8641693 | Locke et al. | Feb 2014 | B2 |
8659420 | Salvat et al. | Feb 2014 | B2 |
8676597 | Buehler et al. | Mar 2014 | B2 |
8689008 | Rangadass et al. | Apr 2014 | B2 |
8694600 | Gaines et al. | Apr 2014 | B2 |
8706537 | Young et al. | Apr 2014 | B1 |
8725528 | Locke et al. | May 2014 | B2 |
8756078 | Collins et al. | Jun 2014 | B2 |
8757485 | Drees et al. | Jun 2014 | B2 |
8758315 | Chen et al. | Jun 2014 | B2 |
8768441 | De Zwart et al. | Jul 2014 | B2 |
8769625 | Wang et al. | Jul 2014 | B2 |
8781847 | Simms et al. | Jul 2014 | B2 |
8795171 | Adamczyk | Aug 2014 | B2 |
8795244 | Randolph et al. | Aug 2014 | B2 |
8838136 | Carnes et al. | Sep 2014 | B2 |
8862393 | Zhou et al. | Oct 2014 | B2 |
8868794 | Masoud et al. | Oct 2014 | B2 |
8874035 | Sherman et al. | Oct 2014 | B2 |
8887100 | Cook et al. | Nov 2014 | B1 |
8890656 | Pendse | Nov 2014 | B2 |
8897198 | Gaines et al. | Nov 2014 | B2 |
8902278 | Pinter et al. | Dec 2014 | B2 |
8905959 | Basaglia | Dec 2014 | B2 |
8909595 | Gandy et al. | Dec 2014 | B2 |
8912897 | Carnes | Dec 2014 | B2 |
8922377 | Carnes | Dec 2014 | B2 |
8945073 | Croizat et al. | Feb 2015 | B2 |
8947237 | Margon et al. | Feb 2015 | B2 |
8978026 | Charlton et al. | Mar 2015 | B2 |
8996393 | Sobie | Mar 2015 | B2 |
9047648 | Lekutai et al. | Jun 2015 | B1 |
9058634 | Buan et al. | Jun 2015 | B2 |
9081885 | Bangera et al. | Jul 2015 | B2 |
9087141 | Huang et al. | Jul 2015 | B2 |
9092705 | Zhuang | Jul 2015 | B2 |
9098114 | Potter et al. | Aug 2015 | B2 |
9105006 | Williamson | Aug 2015 | B2 |
9114054 | Bennett | Aug 2015 | B2 |
9117012 | Basaglia | Aug 2015 | B2 |
9135398 | Kaib et al. | Sep 2015 | B2 |
9141270 | Stuart et al. | Sep 2015 | B1 |
9159148 | Boyer et al. | Oct 2015 | B2 |
9215516 | Carnes et al. | Dec 2015 | B2 |
9215581 | Julian et al. | Dec 2015 | B2 |
9230420 | Lee et al. | Jan 2016 | B2 |
9268827 | Fernandez | Feb 2016 | B2 |
9286443 | Ford et al. | Mar 2016 | B2 |
9323893 | Berry et al. | Apr 2016 | B2 |
9332363 | Jain et al. | May 2016 | B2 |
9338819 | Meng et al. | May 2016 | B2 |
9424020 | Borges et al. | Aug 2016 | B2 |
9427159 | Chang | Aug 2016 | B2 |
9436645 | Al-Ali et al. | Sep 2016 | B2 |
9436800 | Forrester | Sep 2016 | B2 |
9439584 | De Vries et al. | Sep 2016 | B1 |
9460431 | Curry | Oct 2016 | B2 |
9474679 | Locke et al. | Oct 2016 | B2 |
9483614 | Ash et al. | Nov 2016 | B2 |
9539373 | Jones et al. | Jan 2017 | B2 |
9545466 | Locke et al. | Jan 2017 | B2 |
9558331 | Orona et al. | Jan 2017 | B2 |
9585565 | Carnes | Mar 2017 | B2 |
9589247 | Bolene et al. | Mar 2017 | B2 |
9602952 | Kang et al. | Mar 2017 | B2 |
9629986 | Patel et al. | Apr 2017 | B2 |
9658066 | Yuen et al. | May 2017 | B2 |
9662438 | Kamen et al. | May 2017 | B2 |
9687618 | Steinhauer et al. | Jun 2017 | B2 |
9693691 | Johnson | Jul 2017 | B2 |
9700462 | Debusk et al. | Jul 2017 | B2 |
9716757 | Fernandes | Jul 2017 | B2 |
9740825 | Sansale et al. | Aug 2017 | B2 |
9741084 | Holmes et al. | Aug 2017 | B2 |
9787842 | Brooksby et al. | Oct 2017 | B1 |
9792660 | Cannon et al. | Oct 2017 | B2 |
9817948 | Swank | Nov 2017 | B2 |
9818164 | Nolte et al. | Nov 2017 | B2 |
9838645 | Hyde et al. | Dec 2017 | B2 |
9864066 | Park et al. | Jan 2018 | B2 |
9878081 | Leiendecker et al. | Jan 2018 | B2 |
9905123 | Lawhorn | Feb 2018 | B2 |
9928478 | Ragusky et al. | Mar 2018 | B2 |
9974492 | Dicks et al. | May 2018 | B1 |
9990466 | Debusk et al. | Jun 2018 | B2 |
9996681 | Suarez et al. | Jun 2018 | B2 |
10049346 | Jensen et al. | Aug 2018 | B2 |
10061894 | Sethumadhavan et al. | Aug 2018 | B2 |
10095649 | Joshua et al. | Oct 2018 | B2 |
10127357 | Whiting et al. | Nov 2018 | B2 |
10152575 | Sexton et al. | Dec 2018 | B2 |
10173008 | Simpson et al. | Jan 2019 | B2 |
10185834 | Adam et al. | Jan 2019 | B2 |
10207031 | Toth | Feb 2019 | B2 |
10328188 | Deutsch et al. | Jun 2019 | B2 |
20020087360 | Pettit | Jul 2002 | A1 |
20020128804 | Geva | Sep 2002 | A1 |
20020128869 | Kuth | Sep 2002 | A1 |
20020135336 | Zhou et al. | Sep 2002 | A1 |
20020177757 | Britton | Nov 2002 | A1 |
20020184055 | Naghavi et al. | Dec 2002 | A1 |
20030009244 | Engleson et al. | Jan 2003 | A1 |
20030018736 | Christ et al. | Jan 2003 | A1 |
20030105649 | Sheiner et al. | Jun 2003 | A1 |
20030182158 | Son | Sep 2003 | A1 |
20030221687 | Kaigler | Dec 2003 | A1 |
20030229518 | Abraham-Fuchs et al. | Dec 2003 | A1 |
20040006492 | Watanabe | Jan 2004 | A1 |
20040054775 | Poliac et al. | Mar 2004 | A1 |
20040078223 | Sacco et al. | Apr 2004 | A1 |
20040143458 | Pulkkinen et al. | Jul 2004 | A1 |
20040158193 | Bui | Aug 2004 | A1 |
20040167802 | Takada et al. | Aug 2004 | A1 |
20040167804 | Simpson et al. | Aug 2004 | A1 |
20040172301 | Mihai et al. | Sep 2004 | A1 |
20040181433 | Blair | Sep 2004 | A1 |
20040193449 | Wildman et al. | Sep 2004 | A1 |
20040204962 | Howser et al. | Oct 2004 | A1 |
20050033124 | Kelly et al. | Feb 2005 | A1 |
20050055225 | Mehl | Mar 2005 | A1 |
20050055242 | Bello et al. | Mar 2005 | A1 |
20050055244 | Mullan et al. | Mar 2005 | A1 |
20050060211 | Xiao et al. | Mar 2005 | A1 |
20050065817 | Mihai et al. | Mar 2005 | A1 |
20050097200 | Denning, Jr. et al. | May 2005 | A1 |
20050102167 | Kapoor | May 2005 | A1 |
20050108046 | Craft | May 2005 | A1 |
20050108057 | Cohen et al. | May 2005 | A1 |
20050114176 | Dominick et al. | May 2005 | A1 |
20050119914 | Batch | Jun 2005 | A1 |
20050222873 | Nephin et al. | Oct 2005 | A1 |
20050240111 | Chung | Oct 2005 | A1 |
20050283382 | Donoghue et al. | Dec 2005 | A1 |
20060004604 | White | Jan 2006 | A1 |
20060064323 | Alleckson et al. | Mar 2006 | A1 |
20060085393 | Modesitt | Apr 2006 | A1 |
20060089539 | Miodownik et al. | Apr 2006 | A1 |
20060095853 | Amyot et al. | May 2006 | A1 |
20060155584 | Aggarwal | Jul 2006 | A1 |
20060161460 | Smitherman et al. | Jul 2006 | A1 |
20060190130 | Fedor et al. | Aug 2006 | A1 |
20060195843 | Hall | Aug 2006 | A1 |
20060224051 | Teller et al. | Oct 2006 | A1 |
20060246922 | Gasbarro et al. | Nov 2006 | A1 |
20070136099 | Neligh et al. | Jun 2007 | A1 |
20070156456 | McGillin et al. | Jul 2007 | A1 |
20070197881 | Wolf et al. | Aug 2007 | A1 |
20070219826 | Brodsky et al. | Sep 2007 | A1 |
20070255116 | Mehta et al. | Nov 2007 | A1 |
20070271298 | Juang et al. | Nov 2007 | A1 |
20080009681 | Al | Jan 2008 | A1 |
20080086357 | Choubey et al. | Apr 2008 | A1 |
20080091659 | McFaul | Apr 2008 | A1 |
20080119705 | Patel et al. | May 2008 | A1 |
20080126126 | Ballai | May 2008 | A1 |
20080140160 | Goetz et al. | Jun 2008 | A1 |
20080167534 | Young et al. | Jul 2008 | A1 |
20080177579 | Dehaan | Jul 2008 | A1 |
20080221396 | Garces et al. | Sep 2008 | A1 |
20080242945 | Gugliotti et al. | Oct 2008 | A1 |
20080312953 | Claus | Dec 2008 | A1 |
20090037220 | Chambers et al. | Feb 2009 | A1 |
20090048492 | Rantala et al. | Feb 2009 | A1 |
20090048865 | Breazeale, Jr. | Feb 2009 | A1 |
20090097623 | Bharadwaj | Apr 2009 | A1 |
20090099866 | Newman | Apr 2009 | A1 |
20090099867 | Newman | Apr 2009 | A1 |
20090115663 | Brown et al. | May 2009 | A1 |
20090118591 | Kim et al. | May 2009 | A1 |
20090125331 | Pamsgaard et al. | May 2009 | A1 |
20090136909 | Asukai et al. | May 2009 | A1 |
20090144091 | Rago | Jun 2009 | A1 |
20090157429 | Lee et al. | Jun 2009 | A1 |
20090163774 | Thatha et al. | Jun 2009 | A1 |
20090171166 | Amundson et al. | Jul 2009 | A1 |
20090177495 | Abousy et al. | Jul 2009 | A1 |
20090187424 | Grabowski | Jul 2009 | A1 |
20090204434 | Breazeale, Jr. | Aug 2009 | A1 |
20090204435 | Gale | Aug 2009 | A1 |
20090205042 | Zhou et al. | Aug 2009 | A1 |
20090224889 | Aggarwal et al. | Sep 2009 | A1 |
20090270833 | Debelser et al. | Oct 2009 | A1 |
20090281822 | Warner et al. | Nov 2009 | A1 |
20090281830 | McNames et al. | Nov 2009 | A1 |
20090281867 | Sievenpiper et al. | Nov 2009 | A1 |
20090326339 | Horvitz | Dec 2009 | A1 |
20090327102 | Maniar et al. | Dec 2009 | A1 |
20100001838 | Miodownik et al. | Jan 2010 | A1 |
20100017471 | Brown et al. | Jan 2010 | A1 |
20100022848 | Lee et al. | Jan 2010 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100030302 | Blowers et al. | Feb 2010 | A1 |
20100036333 | Schenk, III et al. | Feb 2010 | A1 |
20100090004 | Sands et al. | Apr 2010 | A1 |
20100106528 | Brackett et al. | Apr 2010 | A1 |
20100113908 | Vargas et al. | May 2010 | A1 |
20100145161 | Niyato et al. | Jun 2010 | A1 |
20100222645 | Nadler et al. | Sep 2010 | A1 |
20100234708 | Buck et al. | Sep 2010 | A1 |
20100255876 | Jordan et al. | Oct 2010 | A1 |
20110004188 | Shekalim | Jan 2011 | A1 |
20110066110 | Fathallah et al. | Mar 2011 | A1 |
20110071844 | Cannon et al. | Mar 2011 | A1 |
20110073107 | Rodman et al. | Mar 2011 | A1 |
20110077605 | Karpowicz et al. | Mar 2011 | A1 |
20110106561 | Eaton, Jr. et al. | May 2011 | A1 |
20110137759 | Wellington et al. | Jun 2011 | A1 |
20110145018 | Fotsch et al. | Jun 2011 | A1 |
20110173028 | Bond | Jul 2011 | A1 |
20110184754 | Park et al. | Jul 2011 | A1 |
20110225008 | Elkouh et al. | Sep 2011 | A1 |
20110225499 | Lu | Sep 2011 | A1 |
20110246219 | Smith et al. | Oct 2011 | A1 |
20110275353 | Liu | Nov 2011 | A1 |
20110288878 | Blair | Nov 2011 | A1 |
20120029312 | Beaudry et al. | Feb 2012 | A1 |
20120029313 | Burdett et al. | Feb 2012 | A1 |
20120032819 | Chae et al. | Feb 2012 | A1 |
20120035427 | Friedman et al. | Feb 2012 | A1 |
20120077605 | Nakagaito et al. | Mar 2012 | A1 |
20120081225 | Waugh et al. | Apr 2012 | A1 |
20120089369 | Abuzeni et al. | Apr 2012 | A1 |
20120123323 | Kagan et al. | May 2012 | A1 |
20120123796 | McFaul | May 2012 | A1 |
20120157889 | Tanis et al. | Jun 2012 | A1 |
20120181405 | Zlatic et al. | Jul 2012 | A1 |
20120182143 | Gaines et al. | Jul 2012 | A1 |
20120191475 | Pandey | Jul 2012 | A1 |
20120212455 | Kloeffel | Aug 2012 | A1 |
20120215455 | Patil et al. | Aug 2012 | A1 |
20120259651 | Mallon et al. | Oct 2012 | A1 |
20120271256 | Locke et al. | Oct 2012 | A1 |
20120290217 | Shoval et al. | Nov 2012 | A1 |
20120295566 | Collins et al. | Nov 2012 | A1 |
20120310205 | Lee et al. | Dec 2012 | A1 |
20130018355 | Brand et al. | Jan 2013 | A1 |
20130035615 | Hsieh | Feb 2013 | A1 |
20130045764 | Vik et al. | Feb 2013 | A1 |
20130073303 | Hsu | Mar 2013 | A1 |
20130076528 | Boettner et al. | Mar 2013 | A1 |
20130087609 | Nichol et al. | Apr 2013 | A1 |
20130090949 | Tibebu | Apr 2013 | A1 |
20130103419 | Beaudry | Apr 2013 | A1 |
20130124227 | Ellis | May 2013 | A1 |
20130132855 | Manicka et al. | May 2013 | A1 |
20130150686 | Fronterhouse et al. | Jun 2013 | A1 |
20130150698 | Hsu et al. | Jun 2013 | A1 |
20130151274 | Bage et al. | Jun 2013 | A1 |
20130157571 | Wondka et al. | Jun 2013 | A1 |
20130159456 | Daoud et al. | Jun 2013 | A1 |
20130160082 | Miller | Jun 2013 | A1 |
20130186405 | Krzyzanowski et al. | Jul 2013 | A1 |
20130190903 | Balakrishnan et al. | Jul 2013 | A1 |
20130191513 | Kamen et al. | Jul 2013 | A1 |
20130196703 | Masoud et al. | Aug 2013 | A1 |
20130204106 | Bennett | Aug 2013 | A1 |
20130211206 | Sands et al. | Aug 2013 | A1 |
20130211854 | Wagstaff | Aug 2013 | A1 |
20130212168 | Bonasera et al. | Aug 2013 | A1 |
20130214925 | Weiss | Aug 2013 | A1 |
20130218053 | Kaiser et al. | Aug 2013 | A1 |
20130226607 | Woody et al. | Aug 2013 | A1 |
20130227128 | Wagstaff | Aug 2013 | A1 |
20130231596 | Hornbach et al. | Sep 2013 | A1 |
20130245387 | Patel | Sep 2013 | A1 |
20130253952 | Burke et al. | Sep 2013 | A1 |
20130255681 | Batch et al. | Oct 2013 | A1 |
20130267919 | Caso et al. | Oct 2013 | A1 |
20130268283 | Vann et al. | Oct 2013 | A1 |
20130271556 | Ross et al. | Oct 2013 | A1 |
20130282395 | Rustgi et al. | Oct 2013 | A1 |
20130285837 | Uchida | Oct 2013 | A1 |
20130297350 | Gross et al. | Nov 2013 | A1 |
20130304489 | Miller | Nov 2013 | A1 |
20130310726 | Miller et al. | Nov 2013 | A1 |
20130317753 | Kamen et al. | Nov 2013 | A1 |
20130325508 | Johnson et al. | Dec 2013 | A1 |
20130331748 | Wright et al. | Dec 2013 | A1 |
20130332197 | Hinkel | Dec 2013 | A1 |
20130335233 | Kamar et al. | Dec 2013 | A1 |
20130339049 | Blumberg, Jr. et al. | Dec 2013 | A1 |
20130345524 | Meyer et al. | Dec 2013 | A1 |
20140002234 | Alwan | Jan 2014 | A1 |
20140005618 | Locke et al. | Jan 2014 | A1 |
20140028464 | Garibaldi | Jan 2014 | A1 |
20140031884 | Elghazzawi | Jan 2014 | A1 |
20140032231 | Semen et al. | Jan 2014 | A1 |
20140058714 | Boyer | Feb 2014 | A1 |
20140087762 | Galvin et al. | Mar 2014 | A1 |
20140108033 | Akbay et al. | Apr 2014 | A1 |
20140108034 | Akbay et al. | Apr 2014 | A1 |
20140108035 | Akbay et al. | Apr 2014 | A1 |
20140129250 | Daniel et al. | May 2014 | A1 |
20140148138 | Chou | May 2014 | A1 |
20140163919 | Manigel | Jun 2014 | A1 |
20140171753 | Montejo et al. | Jun 2014 | A1 |
20140187888 | Hatziantoniou | Jul 2014 | A1 |
20140207090 | Jian | Jul 2014 | A1 |
20140222446 | Ash et al. | Aug 2014 | A1 |
20140235975 | Carnes | Aug 2014 | A1 |
20140244285 | Hinkle et al. | Aug 2014 | A1 |
20140244301 | Lee et al. | Aug 2014 | A1 |
20140244307 | Shutko et al. | Aug 2014 | A1 |
20140266713 | Sehgal et al. | Sep 2014 | A1 |
20140275876 | Hansen et al. | Sep 2014 | A1 |
20140278502 | Laskin | Sep 2014 | A1 |
20140280882 | Lacerte et al. | Sep 2014 | A1 |
20140297299 | Lester, IV | Oct 2014 | A1 |
20140316819 | Dunsirn et al. | Oct 2014 | A1 |
20140350966 | Khatana et al. | Nov 2014 | A1 |
20140366878 | Baron | Dec 2014 | A1 |
20140372147 | White | Dec 2014 | A1 |
20140372522 | Orona et al. | Dec 2014 | A1 |
20140375470 | Malveaux | Dec 2014 | A1 |
20140378895 | Barack | Dec 2014 | A1 |
20150012290 | Inciardi et al. | Jan 2015 | A1 |
20150019237 | Doyle et al. | Jan 2015 | A1 |
20150019257 | Doyle et al. | Jan 2015 | A1 |
20150025486 | Hu et al. | Jan 2015 | A1 |
20150046137 | Zeilinger | Feb 2015 | A1 |
20150066531 | Jacobson et al. | Mar 2015 | A1 |
20150072613 | Swanson | Mar 2015 | A1 |
20150094830 | Lipoma et al. | Apr 2015 | A1 |
20150095056 | Ryan et al. | Apr 2015 | A1 |
20150095059 | Yegge et al. | Apr 2015 | A1 |
20150095066 | Ryan et al. | Apr 2015 | A1 |
20150095068 | Ryan et al. | Apr 2015 | A1 |
20150100340 | Folsom et al. | Apr 2015 | A1 |
20150112707 | Manice et al. | Apr 2015 | A1 |
20150118662 | Ellison et al. | Apr 2015 | A1 |
20150119652 | Hyde et al. | Apr 2015 | A1 |
20150120318 | Toyama | Apr 2015 | A1 |
20150133829 | DeBusk | May 2015 | A1 |
20150143300 | Zhang et al. | May 2015 | A1 |
20150164323 | Holtzclaw | Jun 2015 | A1 |
20150164376 | Huang | Jun 2015 | A1 |
20150186615 | Armor et al. | Jul 2015 | A1 |
20150189001 | Lee et al. | Jul 2015 | A1 |
20150227716 | Ryan et al. | Aug 2015 | A1 |
20150227717 | Ryan et al. | Aug 2015 | A1 |
20150234557 | Dorn | Aug 2015 | A1 |
20150234995 | Casady et al. | Aug 2015 | A1 |
20150242578 | Siemon | Aug 2015 | A1 |
20150242583 | Edson | Aug 2015 | A1 |
20150254403 | Laperna | Sep 2015 | A1 |
20150257643 | Watson et al. | Sep 2015 | A1 |
20150261920 | Blick | Sep 2015 | A1 |
20150269323 | Ginsburg | Sep 2015 | A1 |
20150286970 | Dickerson et al. | Oct 2015 | A1 |
20150304478 | Kim et al. | Oct 2015 | A1 |
20150310182 | Henze et al. | Oct 2015 | A1 |
20150324943 | Han et al. | Nov 2015 | A1 |
20150339445 | Gruby et al. | Nov 2015 | A1 |
20150343188 | Allan | Dec 2015 | A1 |
20150363058 | Chung et al. | Dec 2015 | A1 |
20150370984 | Russell et al. | Dec 2015 | A1 |
20150370997 | Krongrad et al. | Dec 2015 | A1 |
20150379441 | Syed et al. | Dec 2015 | A1 |
20160004824 | Stanton et al. | Jan 2016 | A1 |
20160018963 | Robbins et al. | Jan 2016 | A1 |
20160042154 | Goldberg et al. | Feb 2016 | A1 |
20160044141 | Pfützenreuter et al. | Feb 2016 | A1 |
20160055310 | Bentley et al. | Feb 2016 | A1 |
20160058286 | Joshua et al. | Mar 2016 | A1 |
20160063210 | Bardi et al. | Mar 2016 | A1 |
20160066864 | Frieder et al. | Mar 2016 | A1 |
20160080365 | Baker et al. | Mar 2016 | A1 |
20160085415 | Humphrys et al. | Mar 2016 | A1 |
20160098524 | Himmelstein | Apr 2016 | A1 |
20160110507 | Abbo | Apr 2016 | A1 |
20160128571 | Adler | May 2016 | A1 |
20160129186 | Douglas et al. | May 2016 | A1 |
20160135752 | Beaumont | May 2016 | A1 |
20160142443 | Ting et al. | May 2016 | A1 |
20160151015 | Condurso et al. | Jun 2016 | A1 |
20160154936 | Kalathil | Jun 2016 | A1 |
20160154943 | Cho et al. | Jun 2016 | A1 |
20160171866 | Dupasquier et al. | Jun 2016 | A1 |
20160180031 | Slater | Jun 2016 | A1 |
20160184497 | Phillips et al. | Jun 2016 | A1 |
20160196399 | Bonhomme | Jul 2016 | A1 |
20160203275 | Benjamin et al. | Jul 2016 | A1 |
20160203283 | Baruah et al. | Jul 2016 | A1 |
20160209837 | Kim | Jul 2016 | A1 |
20160212577 | Dor et al. | Jul 2016 | A1 |
20160217433 | Walton et al. | Jul 2016 | A1 |
20160246943 | Lake et al. | Aug 2016 | A1 |
20160260035 | Crooks et al. | Sep 2016 | A1 |
20160287189 | Modai et al. | Oct 2016 | A1 |
20160308969 | Aihara et al. | Oct 2016 | A1 |
20160321404 | Ginsburg | Nov 2016 | A1 |
20160321422 | Albright | Nov 2016 | A1 |
20170007494 | Rock et al. | Jan 2017 | A1 |
20170014028 | Clear, Jr. | Jan 2017 | A1 |
20170017765 | Yegge et al. | Jan 2017 | A1 |
20170032648 | McClain et al. | Feb 2017 | A1 |
20170046503 | Cho et al. | Feb 2017 | A1 |
20170053073 | Allen et al. | Feb 2017 | A1 |
20170055205 | Morris et al. | Feb 2017 | A1 |
20170068781 | Zasowski et al. | Mar 2017 | A1 |
20170074717 | Pilkington et al. | Mar 2017 | A1 |
20170078396 | Haas et al. | Mar 2017 | A1 |
20170116373 | Ginsburg et al. | Apr 2017 | A1 |
20170140120 | Thrower | May 2017 | A1 |
20170150939 | Shah | Jun 2017 | A1 |
20170193181 | Carter et al. | Jul 2017 | A1 |
20170212995 | Ingmanson | Jul 2017 | A1 |
20170257682 | Shtalryd | Sep 2017 | A1 |
20170270533 | Barton et al. | Sep 2017 | A1 |
20170273116 | Elghazzawi | Sep 2017 | A1 |
20170327371 | Bai et al. | Nov 2017 | A1 |
20170372010 | Doherty et al. | Dec 2017 | A1 |
20180004908 | Barrus et al. | Jan 2018 | A1 |
20180052454 | Magno et al. | Feb 2018 | A1 |
20180121629 | Dyer et al. | May 2018 | A1 |
20180139572 | Hansen | May 2018 | A1 |
20180144817 | Lofgren et al. | May 2018 | A1 |
20180158545 | Blomquist | Jun 2018 | A1 |
20180160907 | Verma | Jun 2018 | A1 |
20180181714 | Pillarisetty et al. | Jun 2018 | A1 |
20180233016 | Daniel et al. | Aug 2018 | A1 |
20180233221 | Blomquist | Aug 2018 | A1 |
20180279880 | Bacchi | Oct 2018 | A1 |
20180286502 | Lane et al. | Oct 2018 | A1 |
20180308569 | Luellen | Oct 2018 | A1 |
20180308573 | Hochrein et al. | Oct 2018 | A1 |
20180315492 | Bishop et al. | Nov 2018 | A1 |
20180322944 | Valdizan | Nov 2018 | A1 |
Number | Date | Country |
---|---|---|
102961815 | Mar 2013 | CN |
104721892 | Jun 2015 | CN |
102010036405 | Jan 2012 | DE |
0980227 | Feb 2000 | EP |
0566381 | Jul 2002 | EP |
1231965 | Aug 2002 | EP |
1291802 | Mar 2003 | EP |
1309960 | May 2003 | EP |
0814864 | Dec 2003 | EP |
1407624 | Apr 2004 | EP |
1011420 | Dec 2004 | EP |
1495713 | Jan 2005 | EP |
1524619 | Apr 2005 | EP |
1540557 | Jun 2005 | EP |
1579367 | Sep 2005 | EP |
1587017 | Oct 2005 | EP |
1788503 | May 2007 | EP |
1839244 | Oct 2007 | EP |
1839615 | Oct 2007 | EP |
1857950 | Nov 2007 | EP |
1870068 | Dec 2007 | EP |
1904964 | Apr 2008 | EP |
1934852 | Jun 2008 | EP |
1975828 | Oct 2008 | EP |
1993435 | Nov 2008 | EP |
2038786 | Mar 2009 | EP |
2040604 | Apr 2009 | EP |
2092470 | Aug 2009 | EP |
2146297 | Jan 2010 | EP |
2172859 | Apr 2010 | EP |
2214552 | Aug 2010 | EP |
2218478 | Aug 2010 | EP |
1404213 | Mar 2011 | EP |
1247229 | Apr 2011 | EP |
1406540 | Jun 2011 | EP |
1812094 | Aug 2011 | EP |
2384472 | Nov 2011 | EP |
2226002 | Jan 2012 | EP |
1610494 | Mar 2012 | EP |
1248660 | Apr 2012 | EP |
2023800 | Apr 2012 | EP |
2451513 | May 2012 | EP |
1248661 | Aug 2012 | EP |
2488977 | Aug 2012 | EP |
2562665 | Feb 2013 | EP |
2619723 | Jul 2013 | EP |
1881784 | Oct 2013 | EP |
2664194 | Nov 2013 | EP |
2743850 | Jun 2014 | EP |
2745204 | Jun 2014 | EP |
1684146 | Jul 2014 | EP |
2795492 | Oct 2014 | EP |
2841895 | Mar 2015 | EP |
2850771 | Mar 2015 | EP |
2876567 | May 2015 | EP |
2891999 | Jul 2015 | EP |
2894581 | Jul 2015 | EP |
2906101 | Aug 2015 | EP |
2945084 | Nov 2015 | EP |
2962266 | Jan 2016 | EP |
2968829 | Jan 2016 | EP |
2973089 | Jan 2016 | EP |
3000082 | Mar 2016 | EP |
3010398 | Apr 2016 | EP |
3054389 | Aug 2016 | EP |
3070628 | Sep 2016 | EP |
3078010 | Oct 2016 | EP |
3096113 | Nov 2016 | EP |
2563437 | Mar 2017 | EP |
2773393 | Mar 2017 | EP |
3134854 | Mar 2017 | EP |
3027242 | Apr 2017 | EP |
2556650 | May 2017 | EP |
3174569 | Jun 2017 | EP |
2632407 | Aug 2017 | EP |
3209358 | Aug 2017 | EP |
3041571 | Sep 2017 | EP |
2856767 | Nov 2017 | EP |
3252635 | Dec 2017 | EP |
2320971 | May 2018 | EP |
2335173 | May 2018 | EP |
3100188 | Jun 2018 | EP |
3330973 | Jun 2018 | EP |
3352174 | Jul 2018 | EP |
2440112 | Oct 2018 | EP |
3400549 | Nov 2018 | EP |
2992500 | Dec 2018 | EP |
2597584 | Jan 2019 | EP |
3219340 | Jan 2019 | EP |
2890456 | Feb 2019 | EP |
3377130 | Apr 2019 | EP |
2881875 | May 2019 | EP |
2836269 | Aug 2019 | EP |
2409951 | Jul 2005 | GB |
2436160 | Sep 2007 | GB |
2449400 | Nov 2008 | GB |
2456708 | Jul 2009 | GB |
2423178 | May 2010 | GB |
2475091 | May 2011 | GB |
2488904 | Sep 2012 | GB |
2446923 | May 2013 | GB |
2499986 | Sep 2013 | GB |
2491946 | Aug 2014 | GB |
2499873 | May 2016 | GB |
2533910 | Jul 2016 | GB |
2541286 | Feb 2017 | GB |
2550576 | Jun 2018 | GB |
WO 9627163 | Sep 1996 | WO |
WO 9744745 | Nov 1997 | WO |
WO 9924927 | May 1999 | WO |
WO 9963886 | Dec 1999 | WO |
WO 0032088 | Jun 2000 | WO |
WO 0060522 | Oct 2000 | WO |
WO 0133457 | May 2001 | WO |
WO 0181829 | Nov 2001 | WO |
WO 0217075 | Feb 2002 | WO |
WO 0233577 | Apr 2002 | WO |
WO 02078594 | Oct 2002 | WO |
WO 02101713 | Dec 2002 | WO |
WO 03054668 | Jul 2003 | WO |
WO 2004057514 | Jul 2004 | WO |
WO 2004074457 | Sep 2004 | WO |
WO 2005022349 | Mar 2005 | WO |
WO 2005031632 | Apr 2005 | WO |
WO 2005036447 | Apr 2005 | WO |
WO 2005045461 | May 2005 | WO |
WO 2005053793 | Jun 2005 | WO |
WO 2005057466 | Jun 2005 | WO |
WO 2005083619 | Sep 2005 | WO |
WO 2005101282 | Oct 2005 | WO |
WO 2005109297 | Nov 2005 | WO |
WO 2005120097 | Dec 2005 | WO |
WO 2006021154 | Mar 2006 | WO |
WO 2006066583 | Jun 2006 | WO |
WO 2006066585 | Jun 2006 | WO |
WO 2006071711 | Jul 2006 | WO |
WO 2006099120 | Sep 2006 | WO |
WO 2006108304 | Oct 2006 | WO |
WO 2006108858 | Oct 2006 | WO |
WO 2006111109 | Oct 2006 | WO |
WO 2007027490 | Mar 2007 | WO |
WO 2007035646 | Mar 2007 | WO |
WO 2007127879 | Nov 2007 | WO |
WO 2007133478 | Nov 2007 | WO |
WO 2007137869 | Dec 2007 | WO |
WO 2008010012 | Jan 2008 | WO |
WO 2008036344 | Mar 2008 | WO |
WO 2008062382 | May 2008 | WO |
WO 2008116295 | Oct 2008 | WO |
WO 2008150633 | Dec 2008 | WO |
WO 2009140669 | Nov 2009 | WO |
WO 2010017484 | Feb 2010 | WO |
WO 2010025166 | Mar 2010 | WO |
WO 2010025467 | Mar 2010 | WO |
WO 2010078558 | Jul 2010 | WO |
WO 2010085033 | Jul 2010 | WO |
WO 2010132617 | Nov 2010 | WO |
WO 2010145780 | Dec 2010 | WO |
WO 2011005633 | Jan 2011 | WO |
WO 2011023384 | Mar 2011 | WO |
WO 2011039676 | Apr 2011 | WO |
WO 2011046860 | Apr 2011 | WO |
WO 2011047334 | Apr 2011 | WO |
WO 2011123933 | Oct 2011 | WO |
WO 2011137230 | Nov 2011 | WO |
WO 2012051278 | Apr 2012 | WO |
WO 2012127281 | Sep 2012 | WO |
WO 2013026999 | Feb 2013 | WO |
WO 2013036853 | Mar 2013 | WO |
WO 2013061887 | May 2013 | WO |
WO 2013102855 | Jul 2013 | WO |
WO 2013109517 | Jul 2013 | WO |
WO 2013138182 | Sep 2013 | WO |
WO 2013141870 | Sep 2013 | WO |
WO 2013155193 | Oct 2013 | WO |
WO 2013175076 | Nov 2013 | WO |
WO 2014015215 | Jan 2014 | WO |
WO 2014018786 | Jan 2014 | WO |
WO 2014075494 | May 2014 | WO |
WO 2014089086 | Jun 2014 | WO |
WO 2014100036 | Jun 2014 | WO |
WO 2014100687 | Jun 2014 | WO |
WO 2014106056 | Jul 2014 | WO |
WO 2014123846 | Aug 2014 | WO |
WO 2014133822 | Sep 2014 | WO |
WO 2014141221 | Sep 2014 | WO |
WO 2014145496 | Sep 2014 | WO |
WO 2014150255 | Sep 2014 | WO |
WO 2014152963 | Sep 2014 | WO |
WO 2014189070 | Nov 2014 | WO |
WO 2014009876 | Dec 2014 | WO |
WO 2015019273 | Feb 2015 | WO |
WO 2015025482 | Feb 2015 | WO |
WO 2015026387 | Feb 2015 | WO |
WO 2015050816 | Apr 2015 | WO |
WO 2015078112 | Jun 2015 | WO |
WO 2015085249 | Jun 2015 | WO |
WO 2015091070 | Jun 2015 | WO |
WO 2015124670 | Aug 2015 | WO |
WO 2015132528 | Sep 2015 | WO |
WO 2015140801 | Sep 2015 | WO |
WO 2015143099 | Sep 2015 | WO |
WO 2015145455 | Oct 2015 | WO |
WO 2015156143 | Oct 2015 | WO |
WO 2015164787 | Oct 2015 | WO |
WO 2015179915 | Dec 2015 | WO |
WO 2015179916 | Dec 2015 | WO |
WO 2015179917 | Dec 2015 | WO |
WO 2015181836 | Dec 2015 | WO |
WO 2015187480 | Dec 2015 | WO |
WO 2016001088 | Jan 2016 | WO |
WO 2016006536 | Jan 2016 | WO |
WO 2016019191 | Feb 2016 | WO |
WO 2016075656 | May 2016 | WO |
WO 2016108163 | Jul 2016 | WO |
WO 2016118318 | Jul 2016 | WO |
WO 2016120820 | Aug 2016 | WO |
WO 2016136694 | Sep 2016 | WO |
WO 2016141799 | Sep 2016 | WO |
WO 2016151364 | Sep 2016 | WO |
WO 2016160849 | Oct 2016 | WO |
WO 2016175649 | Nov 2016 | WO |
WO 2016178936 | Nov 2016 | WO |
WO 2016190978 | Dec 2016 | WO |
WO 2017001848 | Jan 2017 | WO |
WO 2017004423 | Jan 2017 | WO |
WO 2017027729 | Feb 2017 | WO |
WO 2017035024 | Mar 2017 | WO |
WO 2017053384 | Mar 2017 | WO |
WO 2017062042 | Apr 2017 | WO |
WO 2017142100 | Aug 2017 | WO |
WO 2017165895 | Sep 2017 | WO |
WO 2017192673 | Nov 2017 | WO |
WO 2018007100 | Jan 2018 | WO |
WO 2018013666 | Jan 2018 | WO |
WO 2018033819 | Feb 2018 | WO |
WO 2018044894 | Mar 2018 | WO |
WO 2018064234 | Apr 2018 | WO |
WO 2018067593 | Apr 2018 | WO |
WO 2018082813 | May 2018 | WO |
WO 2018091492 | May 2018 | WO |
WO 2018096390 | May 2018 | WO |
WO 2018145880 | Aug 2018 | WO |
WO 2019014141 | Jan 2019 | WO |
Entry |
---|
International Search Report and Written Opinion, re PCT Application No. PCT/US2018/041313, dated Sep. 25, 2018. |
Cinterion., “Cinterion PHS8-P 3G HSPA+,” retrieved from http://www.cinterion.com/tl_files/cinterion/downloads/cinterion_datasheet_PHSS_web.pdf, 2012, 2 pages. |
International Preliminary Report on Patentability for Application No. PCT/US2018/041313, dated Jan. 23, 2020, 9 pages. |
U.S. Appl. No. 60/845,993, filed Sep. 19, 2006, 438 pages. |
Number | Date | Country | |
---|---|---|---|
20200222599 A1 | Jul 2020 | US |
Number | Date | Country | |
---|---|---|---|
62530480 | Jul 2017 | US |